Trial Profile
A Randomized, Double-blind, Placebo Controlled, Phase II Study of Everolimus in Combination With Exemestane in the Treatment of Chinese Postmenopausal Women With Estrogen Receptor Positive, HER-2 Negative, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms BOLERO-5
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 Jun 2022 Status changed from active, no longer recruiting to completed.
- 02 May 2022 Planned End Date changed from 29 Apr 2022 to 11 Nov 2022.
- 17 Jun 2020 Planned End Date changed from 28 Apr 2022 to 29 Apr 2022.